Peripartum cardiomyopathy (PPCMP) is a relatively rare form of dilated cardiomyopathy with unknown etiology. A generally accepted definition comprises the following criteria: 1) cardiac failure occurring in the last month of pregnancy or within 5 months after delivery; 2) absence of an alternative cause for the cardiomyopathy; 3) absence of heart disease before the last month of pregnancy and 4) demonstrated left ventricular dysfunction.
From an intensivists perspective, the diagnosis of PPCMP should always be considered when triaging a woman with peripartum respiratory or hemodynamic distress. Timely diagnosis is crucial to enable prompt initiation of the proper management in order to minimize the risk for serious maternal and neonatal sequelae. Goal-directed echocardiography should be utilized as early as possible, preferably already in the emergency department, to demonstrate or rule out PPCMP. Only then, appropriate supportive measures such as appropriate medical therapy, intra-aortic balloon counter pulsation (IABP), extracorporeal membrane oxygenation (ECMO) or assist device support can be initiated.
Keywords: PPCMP, heart failure in pregnancy, cardiomyopathy, idiopathic cardiomyopathy, heart failure, Peripartum Cardiomyopathy, peripartum respiratory, extracorporeal membrane oxygenation, intra-aortic balloon counter
Statins and Carotid Intima-Media Thickness Reduction: An Up-to-Date Review
Current Medicinal Chemistry Pulmonary Hypertension secondary to Left Heart Disease
Current Vascular Pharmacology Mechanical Circulatory Support for End-Stage Heart Failure in Repaired and Palliated Congenital Heart Disease
Current Cardiology Reviews Prospectives of Antihypertensive Nano-ceuticals as Alternative Therapeutics
Current Drug Targets Vulnerable Plaque Versus Vulnerable Patient: Emerging Blood Biomarkers for Risk Stratification
Endocrine, Metabolic & Immune Disorders - Drug Targets The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors
Current Cancer Drug Targets Triglyceride Level Affecting Shared Susceptibility Genes in Metabolic Syndrome and Coronary Artery Disease
Current Medicinal Chemistry Editorial [Hot Topic: Heart Transplantation in Congenital Heart Disease (Guest Editor: Francesco Parisi)]
Current Cardiology Reviews Impact of Diabetes on Cardiac and Vascular Disease: Role of Calcium Signaling
Current Medicinal Chemistry Treatment of Experimental Myocarditis via Modulation of the Renin-Angiotensin System
Current Pharmaceutical Design Aspirin and Clopidogrel: A Sweeping Combination in Cardiology
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Biomimetic Approaches for Targeted Nanomedicine: Current Status and Future Perspectives
Current Drug Therapy Endothelial Cells Facilitate Cell-Based Cardiac Repair: Progress and Challenge
Current Stem Cell Research & Therapy Disruption of Circadian Rhythms and Sleep on Critical Illness and the Impact on Cardiovascular Events
Current Pharmaceutical Design Associations between Periodontitis and Systemic Inflammatory Diseases: Response to Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Under Re-organization) Mechanical Support in Cardiogenic Shock Complicating Acute Coronary Syndrome: Ready for Prime Time?
Current Vascular Pharmacology Improving RBC K Transport and Hemoglobin-O2 Binding by Amiloride: A Novel Therapeutic Approach for Reversion of Angina and Myocardial Ischemia in Coronary Heart Diseases
Recent Patents on Cardiovascular Drug Discovery (Discontinued) The Renin-Angiotensin Systems: Evolving Pharmacological Perspectives for Cerebroprotection
Current Pharmaceutical Design Recent Developments on Coronary Microvasculopathy after Heart Transplantation:A New Target in the Therapy of Cardiac Allograft Vasculopathy
Current Vascular Pharmacology Troponin in Newborns and Pediatric Patients
Cardiovascular & Hematological Agents in Medicinal Chemistry